2. Search Result
Search Result
Results for "

BPRS

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100865
    BPR1K871

    DBPR114

    		 FLT3 Cancer
    BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor with IC50s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy .
    BPR1K871
  • HY-128865
    BPR1M97

    		Opioid Receptor Neurological Disease
    BPR1M97 is a dual-acting mu opioid receptor (MOP) and nociceptin-orphanin FQ peptide (NOP) receptor agonist with Ki values of 1.8 and 4.2 nM, respectively. BPR1M97 shows high potency and blood-brain barrier penetration, and produces potent antinociceptive effects .
    BPR1M97
  • HY-132935
    BPR1R024

    		c-Fms Inflammation/Immunology Cancer
    BPR1R024 is an orally active and selective colony-stimulating factor-1 receptor (CSF1R) inhibitor. BPR1R024 has potent CSF1R inhibition activity with an IC50 value of 0.53 nM. BPR1R024 can be used for the research of immuno-oncology .
    BPR1R024
  • HY-13537
    BPR1J-097

    		FLT3 Cancer
    BPR1J-097 is a novel potent FLT3 inhibitor with an IC50 of 11 nM.
    BPR1J-097
  • HY-162645
    BPR5K230

    		TAM Receptor Inflammation/Immunology Cancer
    BPR5K230 is a dual inhibitor for the receptor tyrosine kinase MER and AXL, with IC50 of 4.1 nM and 9.2 nM. BPR5K230 inhibits the proliferation of Ba/F3-MER with IC50 of 5 nM. BPR5K230 exhibits good pharmacokinetic characteristics in mice, exhibits anti-inflammatory and antitumor against 4T1, MDA-MB-231, MC38 and Hepa1?6 in mouse models .
    BPR5K230
  • HY-161356
    BPR3P0128

    		DNA/RNA Synthesis SARS-CoV Infection
    BPR3P0128 is an orally active, non-nucleoside RNA-dependent RNA polymerase (RdRp) inhibitor that has been shown to inhibit the activity of various SARS-CoV-2 variants. The EC50 for SARS-CoV-2 and HCoV-229E are 0.62 μM and 0.14 μM. BPR3P0128 demonstrates effective anti-pancoronavirus activity within the submicromolar range. PR3P0128 shows synergistic antiviral activity when combined with Remdesivir (HY-104077) .
    BPR3P0128
  • HY-P4669
    LM-030

    BPR277

    		 Kallikrein Elastase Inflammation/Immunology
    LM-030 (BPR277), cyclic depsipeptide, is a potent kallikrein-related peptidase 7 (KLK7) and human neutrophil elastase inhibitor with IC50 values of 1 and 10 nM. LM-030 can be used for the study of Netherton syndrome .
    LM-030
  • HY-116129
    BPR1J-340

    		FLT3 Apoptosis Cancer
    BPR1J-340 is a potent FLT3 inhibitor with an IC50 of ~25 nM. BPR1J-340 inhibits the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD + acute myeloid leukemia (AML) cells. BPR1J-340 exhibits significant anti-tumor activities .
    BPR1J-340
  • HY-132935A
    BPR1R024 mesylate

    		c-Fms Inflammation/Immunology Cancer
    BPR1R024 mesylate is an orally active and selective colony-stimulating factor-1 receptor (CSF1R) inhibitor. BPR1R024 mesylate is the equivalent of BPR1R024 (HY-132935). BPR1R024 has potent CSF1R inhibition activity with an IC50 value of 0.53 nM. BPR1R024 can be used for the research of immuno-oncology .
    BPR1R024 mesylate
  • HY-13537A
    BPR1J-097 Hydrochloride
    1 Publications Verification

    		 FLT3 Cancer
    BPR1J-097 Hydrochloride is a novel and potent FLT3 inhibitor with an IC50 of 11 nM.
    BPR1J-097 Hydrochloride
  • HY-119800
    Setoperone

    		5-HT Receptor Dopamine Receptor Neurological Disease
    Setoperone is an orally active and potent 5-HT₂ receptor antagonist and a moderate dopamine D₂ receptor blocker. Setoperone dissociates from the receptors relatively quickly, but it is easily "captured" by serotonin receptors in the body, resulting in persistent receptor inhibition even after elution. Setoperone can be used to study the negative symptoms of type II schizophrenia and associated mood disorders .
    Setoperone
  • HY-14140
    BPR-890

    		Cannabinoid Receptor Metabolic Disease
    BPR-890 is a potent agonist of CB1. BPR-890 exhibits excellent CB2/1 selectivity and has in vivo efficacy in diet-induced obese mouse model .
    BPR-890

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: